Who are Switch ritonavir-boosted PI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LPV/r, HIV therapy, Combivir+Kaletra, lopinavir with ritonavir in 1:1 ratio, LPV/r + TDF/FTC or TDF/3TC, Fosamprenavir/ritonavir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/switch-ritonavir-boosted-pi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Switch ritonavir-boosted PI — Competitive Intelligence Brief

Switch ritonavir-boosted PI (Switch ritonavir-boosted PI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (boosted). Area: Infectious Disease.

marketed Protease inhibitor (boosted) HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Switch ritonavir-boosted PI (Switch ritonavir-boosted PI) — Juan A. Arnaiz. A ritonavir-boosted protease inhibitor combination that inhibits HIV protease to prevent viral replication and reduce viral load.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Switch ritonavir-boosted PI TARGET	Switch ritonavir-boosted PI	Juan A. Arnaiz	marketed	Protease inhibitor (boosted)	HIV protease
LPV/r	LPV/r	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Protease inhibitor (PI) combination	HIV protease
HIV therapy	HIV therapy	ViiV Healthcare	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)
Combivir+Kaletra	Combivir+Kaletra	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase and HIV protease
lopinavir with ritonavir in 1:1 ratio	lopinavir with ritonavir in 1:1 ratio	Drugs for Neglected Diseases	marketed	HIV protease inhibitor	HIV protease
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Fosamprenavir/ritonavir	Fosamprenavir/ritonavir	ViiV Healthcare	marketed	HIV protease inhibitor	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (boosted) class)

Community Research Initiative of New England · 1 drug in this class
Juan A. Arnaiz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Switch ritonavir-boosted PI — Competitive Intelligence Brief. https://druglandscape.com/ci/switch-ritonavir-boosted-pi. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab